Speed Is Everything In CGRP Race As Amgen/Novartis Reveal Phase III Data

Amgen and Novartis revealed the first set of Phase III data for a CGRP inhibitor in the treatment of episodic migraine, potentially positioning the companies’ biologic erenumab at the head of the drug class.

Four development programs are neck-and-neck in the race to bring a calcitonin gene-related peptide (CGRP) inhibitor to market, and Amgen Inc. is the first company – with its partner Novartis AG – to report positive Phase III results for their biologic erenumab (AMG 334) in episodic headache sufferers.

Speed of development is key, because Amgen and Novartis may have to be the first anti-CGRP developers to commercialize a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category